Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17260197 | 0.96 | KEAP1 (0.38) | KEAP1NFE2L2SMN1; SMN2HDAC3MAPK1 | |
| SCHEMBL17260199 | 0.96 | KEAP1 (0.38) | KEAP1NFE2L2SMN1; SMN2HDAC3MAPK1 | |
| SCHEMBL2331007 | 0.88 | KEAP1 (0.43) | KEAP1NFE2L2MAPTLMNAMEN1 | |
| SCHEMBL14400927 | 0.86 | HSD17B10 (0.39) | KEAP1NFE2L2CA12CA1CA2 | |
| SCHEMBL13223614 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2MAPK1MAPTALDH1A1 | |
| SCHEMBL13765604 | 0.85 | KEAP1 (0.34) | KEAP1NFE2L2ALOX5 | |
| SCHEMBL9350381 | 0.85 | KEAP1 (0.43) | KEAP1NFE2L2MAPTALDH1A1LMNA | |
| SCHEMBL9348982 | 0.84 | KEAP1 (0.41) | KEAP1NFE2L2MAPTALDH1A1LMNA | |
| SCHEMBL17260194 | 0.83 | KEAP1 (0.32) | KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL17260198 | 0.83 | KEAP1 (0.32) | KEAP1NFE2L2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170336416-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LABORATORIES | 2017-11-23 | — | — | US | claimed |
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LAB (US) | 2015-11-19 | — | — | US | claimed |
| US-20170336416-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LABORATORIES | 2017-11-23 | — | — | US | disclosed |
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LAB (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LAB (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2356458-A1 | ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL | Abbott Laboratories (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010048354-A1 | ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100105150-A1 | ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | APOB, MPO, LPO | KEAP1 1733/4885NFE2L2 885/4885SMN1; SMN2 3272/4885 |
| US-20170336416-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | APOB, MPO, LPO | KEAP1 1733/4885NFE2L2 885/4885SMN1; SMN2 3272/4885 |
| US-20100105150-A1 | ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL | SSB, SERPINB1, LGALS3BP | KEAP1 1804/4885NFE2L2 2248/4885SMN1; SMN2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.